33 results about "Median lethal dose" patented technology

A method for studying toxicity of drugs by using model organism zebra fish comprises the following steps of: selecting 100 to 200 adult zebra fishes, respectively disposing in bottles containing a solution of 30 to 50 mL, keeping the temperature in the bottles substantially constant at 22 to 25 DEG C, randomly grouping, each group containing 10 to 20 fishes, wherein the solution in one of the groups is pure water (blank), the solutions in other groups are medicinal solutions with different concentrations, and 0.5% to 2% dimethylsulfoxide (DMSO) can be added to assist dissolving a drug that has poor water solubility, when an additional solvent comparison group prepared by adding 0.5% to 2% DMSO into the pure water is needed; recording the death number of zebra fishes in the medicinal solutions of different concentrations within 24 h, and calculating the death rate (%); calculating median lethal dose-LD50 by Bliss method according to the experiment result; and representing the acute toxicity by the value of LD50. According to the method, the LD50s of zebra fish of triptolide, matrine and emodin are respectively 5.39*10<-3>, 112.3 and 1.08*10<3> mug / mL. The method can objectively reflect the toxicity of drugs.

The invention discloses superfine oil for abrasive machining of a high-lubrication and high-water-separability bearing. The superfine oil consists of mineral oil, polymeric carboxylic acid, organic amine, a surfactant, a synthetic lubricant, an anticorrosive agent, an extreme-pressure additive and an antioxidant. The superfine oil has an excellent lubricating property, a Bouton tester is used fortesting, and a friction coefficient value of raw oil is less than or equal to 0.1; the superfine oil has excellent water separability, and the separation time of oil and water is less than or equal to 10 min (50 ml of sample is added into 50 ml of water, and the mixture is turned for 10 times); and raw materials in a formula are not toxic and harmful substances which influence the environmental safety and human health, the biological median lethal dose LD50 of the product is more than or equal to 5,000 mg / kg, the median lethal concentration LC50 is more than or equal to 5,000 mg / m<3>, the respiratory mucosa irritation is less than or equal to class 1, and the superfine oil has reliable safety and sanitation quality.

The invention discloses algae-lysing aeromonas sp. and an application thereof in controlling cyanobacterial blooms. The aeromonas sp. GLY-2107, which has a significant algae-lysing activity, is separated from a water body from Lake Taihu, and the preservation number of the aeromonas sp. is CGMCC No.8979; and active algae-lysing ingredients, namely 3-phenmethyl-piperazine-2,5-dione and 3-methylindole, are separated, purified and identified from a metabolic product of the aeromonas sp., wherein the median lethal dose LD50 of the 3-phenmethyl-piperazine-2,5-dione on microcystis aeruginosa 9110 is 4.72 [mu]g / mL and the median lethal dose LD50 of the 3-methylindole on the microcystis aeruginosa 9110 is 1.10 [mu]g / mL. The algae-lysing aeromonas sp. is applicable to research, development and production of novel biological algicides, and is finally applied to the control of the cyanobacterial blooms in lakes.

The invention mainly relates to a screening method of anti-glufosinate-ammonium alfalfa plants, in particular to an anti-glufosinate-ammonium germplasm screening method. A screening method for a culture medium for anti-glufosinate-ammonium alfalfa plants is mainly characterized by comprising the following steps: (1) germinating seeds by the MS (Murashige and Skoog) culture medium; (2) screening the dose; (3) inducing alfalfa seeds through ethylmethane sulfonate median lethal dose; (4) screening the anti-glufosinate-ammonium alfalfa plants; and (5) screening resistant plants again. Compared with the prior art, the method has the advantages of being simple and easy to implement, taking effect quickly, and being capable of obtaining the herbicide resistant alfalfa individual plant in a short term. The method adopts a mutation measure, utilizes a chemical mutagen EMS (ethylmethane sulfonate) to induce the alfalfa seeds to cause point mutation, can screen the herbicide resistant alfalfa individual plant by the culture medium and the soil screening method, can provide a new germplasm resource for conventional breeding and can provide a reference for breeding of herbicide resistant agents of other plants.

The invention discloses an algicidal Shewanella and application thereof in controlling blue algae water bloom. The Shewanella sp. Lzh-2 (CGMCC No.6549) with significant algae-lysed activity is isolated from Tai Hu lake water, and effective algicidal components hexahydro-pyrrolo[1,2-A]pyrazine-1,4-dione and indoline-2,3-dione are isolated, purified and identified from the metabolites of the Shewanella, wherein hexahydro-pyrrolo[1,2-A]pyrazine-1,4-dione has median lethal dose LD50 to Microcystis aeruginosa 9110 of 5.7 Mug / mL and has no lethal effect to Synechococcus BN60, and indoline-2,3-dione has median lethal doses to Microcystis aeruginosa 9110 and Synechococcus BN60 of 12.5 Mug / mL and 34.2 Mug / mL respectively. The Shewanella sp. Lzh-2 can be used for developing and producing novel biological algicides and ultimately used for controlling lake blue algae bloom.

The invention provides rhizoma cimicifugae extractive and two kinds of rhizoma cimicifugae ketone alkali. The rhizoma cimicifugae extractive and pure products of the two kinds of rhizoma cimicifugae ketone alkali can be obtained by utilizing cimicifuga foetida plants as a raw material, extracting through an organic solvent and extracting through a solvent or separating through a chromatograph, and the two kinds of rhizoma cimicifugae ketone alkali are first rhizoma cimicifugae ketone alkali and second rhizoma cimicifugae ketone alkali. The extractive and the two kinds of rhizoma cimicifugae ketone alkali can effectively restrain proliferation and growth of tumor cell lines like a human lung cancer cell line A549, a human stomach cancer cell line MKN7, GSU, a human melanoma cell line A375, a human lung adenocarcinoma cell line NCI-H1975, a human colon cancer cell line Colo-205, a human leukemia cell line HL-60 and the like; the half lethal dose of the first rhizoma cimicifugae ketone alkali and the second rhizoma cimicifugae ketone alkali is in a concentration range of 1.36 to 21.09 mu M, so that the first rhizoma cimicifugae ketone alkali and the second rhizoma cimicifugae ketone alkali have obvious antitumor activity and can be applied to preparation of antitumor medicine. Structural formulas of the first rhizoma cimicifugae ketone alkali (1) and the second rhizoma cimicifugae ketone alkali (2) are shown in the specification.

The invention belongs to the technical field of pharmaceuticals, discloses application of a sarpogrelate containing pharmaceutical composition in treatment of diabetic nephropathy, and specifically discloses the application of a compound pharmaceutical composition taking sarpogrelate and 5-hydroxytryptamine synthesizing inhibitor as pharmaceutical active components in preparation of drugs for treating diabetic nephropathy. The test shows that gene silencing 5-HT synthetase and a 5-HT 2 receptor show good effect on inhibiting in-vitro culture and high glucose-induced oxidative stress of human renal mesangial cell strain, proinflammatory factor and chemotactic factor, and meanwhile, the gene silencing 5-HT synthetase system (Tph1 or AADC) and a 5HT 2 receptor are capable of greatly inhibiting high glucose-inducing effect and performing synergistic effect. With the adoption of the pharmaceutical composition, the diabetic nephropathy caused by high-fat feed feeding and streptozotocin induced diabetic nephropathy can be obviously treated; compared with simple prescription, the compound prescription is high in attenuation, and the lethal amount of mice orally taking the drug is obviouslyhalved.

The invention discloses a Stenotrophomonas sp. strain and application thereof in controlling cyanobacterial blooms. A strain of Stenotrophomonas sp. Lzh-7 (CGMCC No.6548) having significant algae-lysing activity is isolated from Taihu water body. The fact is identified that the effective algae-lysing component hydroquinone is isolated and purified from the metabolites of the strain, wherein the median lethal dose (LD50) of hydroquinone to Microcystis aeruginosa 9110 is 3.9 Mug / mL and the median lethal dose (LD50) of hydroquinone to Synechococcus BN60 is 6.7 Mug / mL. The Stenotrophomonas sp. strain can be applied to the research, development and production of novel biological algaecides and eventually applied to the control of lake cyanobacterial blooms.

The invention discloses a Stenotrophomonas sp. strain and application thereof in controlling cyanobacterial blooms. A strain of Stenotrophomonas sp. Lzh-7 (CGMCC No.6548) having significant algae-lysing activity is isolated from Taihu water body. The fact is identified that the effective algae-lysing component hydroquinone is isolated and purified from the metabolites of the strain, wherein the median lethal dose (LD50) of hydroquinone to Microcystis aeruginosa 9110 is 3.9 Mug / mL and the median lethal dose (LD50) of hydroquinone to Synechococcus BN60 is 6.7 Mug / mL. The Stenotrophomonas sp. strain can be applied to the research, development and production of novel biological algaecides and eventually applied to the control of lake cyanobacterial blooms.

The invention provides application of salvianolic acid K in salvia japonica thunb to preparation of medicine for preventing and treating diabetic nephropathy.Safety of the salvianolic acid K in the salvia japonica thunb in Sinkiang is evaluated objectively and scientifically through experiments, and a dosage basis is provided for experiment research on prevention and treatment of DN; firstly, the median lethal dose (LD 50) is determined through per os acute toxicity tests of mice, on the basis of the tests, in vivo experiments on animals are conducted, the prevention and treatment functions and possible mechanism of action of the salvianolic acid K on DN are determined, an experiment basis is provided for preventing and treating DN through natural medicine, and technical data are provided for further development and utilization of the salvia japonica thunb in Sinkiang.

The invention discloses an acrylate combined casting filling material as well as a preparation method and application thereof. The acrylate combined casting filling material comprises the following components: a main agent and a cross-linking agent, wherein the main agent is a mixture of acrylate; the cross-linking agent is one or a mixture of two of polyethylene glycol diallyl ether and oxidized bisphenol A diallyl ether. As the non-toxic polyethylene glycol diallyl ether and / or oxidized bisphenol A diallyl ether are adopted as the cross-linking agent, the rat oral half lethal dose of the casting material is greater than or equal to 6500mg / kg, the material is actually non-toxic, then a safe operation environment can be provided for construction operators, and the influence on the environment can be reduced to the maximum extent.

The invention belongs to the technical field of chemical extraction of traditional Chinese medicine, particularly relates to an extraction method, a purification method and application of alkaloids inground beetles, and specifically provides an extraction method for extracting the alkaloids from the ground beetles, a purification method for the alkaloids obtained according to the extraction method, application of the alkaloids obtained according to the extraction method or the purified alkaloids obtained according to the purification method, and application of the alkaloids obtained accordingto the extraction method or the purified alkaloids obtained according to the purification method in growth inhibition of gastric carcinoma cells. The extraction method has the advantages that GBA18 can be obtained through separation; experimental determination proves that the obtained products have a good inhibiting effect on gastric cancer and bacteria, and the half lethal dose and the minimum lethal dose are within the safety usage range recommended by the Chinese pharmacopoeia; the technical defects that active ingredients in the ground beetles are unclear in the prior art and applicationof the ground beetles is seriously limited are overcome.

The invention discloses superfine oil for abrasive machining of a high-lubrication and high-water-separability bearing. The superfine oil consists of mineral oil, polymeric carboxylic acid, organic amine, a surfactant, a synthetic lubricant, an anticorrosive agent, an extreme-pressure additive and an antioxidant. The superfine oil has an excellent lubricating property, a Bouton tester is used fortesting, and a friction coefficient value of raw oil is less than or equal to 0.1; the superfine oil has excellent water separability, and the separation time of oil and water is less than or equal to 10 min (50 ml of sample is added into 50 ml of water, and the mixture is turned for 10 times); and raw materials in a formula are not toxic and harmful substances which influence the environmental safety and human health, the biological median lethal dose LD50 of the product is more than or equal to 5,000 mg / kg, the median lethal concentration LC50 is more than or equal to 5,000 mg / m<3>, the respiratory mucosa irritation is less than or equal to class 1, and the superfine oil has reliable safety and sanitation quality.

The invention discloses an analgesic anti-inflammatory composite medicament made from lappaconitine and tetrahydropalmatine, a patch made from the composite medicament and a method for preparing the pThe invention discloses an analgesic anti-inflammatory composite medicament made from lappaconitine and tetrahydropalmatine, a patch made from the composite medicament and a method for preparing the pastrointestinal tracts are avoided, the toxicity and the side effect of the composite medicament are reduced, and the bioavailability and the safe curative effect of the composite medicament are imo gastrointestinal tracts are avoided, the toxicity and the side effect of the composite medicament are reduced, and the bioavailability and the safe curative effect of the composite medicament are improved. The composite medicament is convenient to use without causing patients to be afflicted by pain and is very effective in relieving pain and diminishing inflammation.proved. The composite medicament is convenient to use without causing patients to be afflicted by pain and is very effective in relieving pain and diminishing inflammation.atch. The patch comprises a back lining layer, a medicament storage layer and a protection layer, wherein the medicament storage layer is made from raw materials including the lappaconitine, the tetraatch. The patch comprises a back lining layer, a medicament storage layer and a protection layer, wherein the medicament storage layer is made from raw materials including the lappaconitine, the tetrahydropalmatine and pressure-sensitive adhesive; and the patch is made by adding a proper amount of transdermal enhancerfrom in to the same three raw materials. Experiments and clinical research provehydropalmatine and pressure-sensitive adhesive; and the patch is made by adding a proper amount of transdermal enhancerfrom in to the same three raw materials. Experiments and clinical research provethat the composite medicament made from raw medicament materials of lappaconitine and tetrahydropalmatine according to a certain proportion can reduce the toxicity of the lappaconitine and improve thethat the composite medicament made from raw medicament materials of lappaconitine and tetrahydropalmatine according to a certain proportion can reduce the toxicity of the lappaconitine and improve the median lethal dose (LD 50). Due to the use of the patch made from the composite medicament, the blood concentration can be kept stable for a long time, the first-pass effect on liver and the damage tmedian lethal dose (LD 50). Due to the use of the patch made from the composite medicament, the blood concentration can be kept stable for a long time, the first-pass effect on liver and the damage to g

An anti-tumour activated Tuckahoe sclerotium glucan sulfuric is prepared by: taking fresh Tuckahoe sclerotium, extracting non-water soluble (1->3)-beta- D- glucan with NaOH, solving them in anhydrous dimethylsulfoxide, adding pyridine and chloro-sulfonic acid to react to get glucan sulfuric ester. The glucan sulfuric ester's substituted reaction is of non-selective substitution, occurred at C-6 position of hydroxy, the substitution value of sulfuric ester is 0.66- 1.21, weight-average molecular weight is 0.8X104-16.4X104, and has well water solubility. Testing in vivo and in vitro showed that, the glucan sulfuric ester has obvious inhibit effect for Sarcoma 180 and proliferation of adenocarcinoma of stomach. The toxic testing in small rat prove that half lethal dose of glucan sulfuric ester (LD50)>1600 mg / kg, and without toxic or side effects. The Tuckahoe sclerotium glucan sulfuric ester is capable of use in preparing anti-tumour pharmaceuticals or health food with function of increasing body immunological competence.

The invention belongs to the technical field of bioengineering and particularly relates to a B-cell epitope of VP(viral protein)3 of DHAV (duck hepatitis A virus)-1 as well as an identification method and an application of the B-cell epitope. The identification method of the B-cell epitope comprises the following steps: obtaining a target fragment of the VP3; constructing recombinant expression plasmid pG-EX-VP3, preparing VP3 recombinant protein, preparing a polyclonal antibody of the VP3 recombinant protein, determining the median lethal dose ELD50 of the DHAV-1 on chicken embryos or duck embryos, determining the neutralizing titer of the polyclonal antibody of the VP3 recombinant protein and identifying the B-cell epitope on the VP3. The linear B-cell epitope of the VP3 is predicted with comprehensive application of bioinformatics software, epitope peptide is artificially synthesized, identification is performed on the synthetic epitope peptide in combination with an indirect ELISA (enzyme linked immunosorbent assay) method, and reference can be provided for deep development of follow-up DHAV-1 immunological research, construction of novel diagnostic preparations and development of polypeptide vaccines.